Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioMarin Pharmaceutical Inc gives FY 2014 guidance; earnings guidance above analysts' estimates


Wednesday, 26 Feb 2014 04:05pm EST 

BioMarin Pharmaceutical Inc:Expects FY 2014 total revenues of $650 mln to $680 mln.Expects FY 2014 GAAP net loss of $(255) mln to $(285) mln.Expects FY 2014 non-GAAP net loss of $(100) mln to $(130) mln - Thomson Reuters I/B/E/S.FY 2014 revenue of $673 mln and net loss of $(253) mln - Thomson Reuters I/B/E/S. 

Company Quote

62.08
1.7 +2.82%
23 Jul 2014